Model-informed drug development for apramycin in urinary tract infections
Author Information
Author(s): Hernández-Lozano Irene, Aranzana-Climent Vincent, Cao Sha, Matias Carina, Ulf Hansen Jon, Liepinsh Edgars, Hughes Diarmaid, Hobbie Sven N, Vingsbo Lundberg Carina, Friberg Lena E
Primary Institution: Uppsala University
Hypothesis
Can pharmacokinetic-pharmacodynamic modeling predict effective doses of apramycin for treating complicated urinary tract infections?
Conclusion
The study successfully developed a model that predicts an effective dose of apramycin for treating complicated urinary tract infections in humans.
Supporting Evidence
- The PKPD model showed a significant reduction in bacterial load in kidneys and bladder tissue.
- Simulations suggested that an 11 mg/kg daily dose would be sufficient to achieve bacterial stasis in humans.
- The study integrated longitudinal in vivo data to enhance predictions of drug efficacy.
Takeaway
Researchers used a special model to figure out how much apramycin medicine people need to fight urinary infections. They found that a dose of about 11 mg/kg should work well.
Methodology
The study involved in vitro and in vivo experiments with E. coli strains and developed a pharmacokinetic-pharmacodynamic model to assess apramycin efficacy.
Limitations
The study required a significant number of animals to obtain longitudinal data, which may limit the generalizability of the findings.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website